Chemotherapy: Does Neoadjuvant or Adjuvant Therapy Improve Outcomes?

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Since preoperative chemotherapy has been clearly shown to improve outcomes for patients with Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma, practitioners have attempted to extend the use of adjuvant/neoadjuvant chemotherapy to other types of adult soft tissue sarcoma. Given the high risk of distant recurrence and disease-specific death for patients with soft tissue sarcoma tumors larger than 10 cm, these patients should be considered candidates for neoadjuvant chemotherapy as well as investigational therapies. Yet, potential toxicity from cytotoxic chemotherapy is substantial, and there remains little consensus and wide variation regarding the indications for use of chemotherapy in the adjuvant/neoadjuvant setting.

Original languageEnglish (US)
Pages (from-to)861-872
Number of pages12
JournalSurgical Oncology Clinics of North America
Issue number4
StatePublished - Oct 1 2016


  • Chemotherapy
  • Limb salvage
  • Multimodality therapy
  • Soft tissue sarcoma
  • Surgery
  • Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Chemotherapy: Does Neoadjuvant or Adjuvant Therapy Improve Outcomes?'. Together they form a unique fingerprint.

Cite this